DIAGNOSTIC

Our diagnostic test represents the determination of biomarkers non-related with β-amyloid nor tau. Therefore, our unique value proposition is that our test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next generation sequencing and applying a machine learning approach. As systemic mitochondrial dysfunction has been proposed just before the appearance of cerebral abnormal protein aggregates, our findings may become a pool of biomarkers very useful for the detection of patients at early stages of AD.